Bristol Myers Squibb

Compendium of presentations
Click on date to see a list of scheduled presentations

Table of Contents

Saturday, December 5

Sunday, December 6

Monday, December 7

Publication Only
# Saturday, December 5

## MULTIPLE MYELOMA

### Oral Presentation

**Presentation #131:** Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study  
**Lead Author and Presenter:** Yi Lin, Mayo Clinic, Rochester, MN  
**Session:** Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data  
**Time and Channel:** 10:00AM, Channel: 10

### Poster Presentations

**Presentation #1358:** Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001  
**Lead Author and Presenter:** Michael Amatangelo, Bristol Myers Squibb, Princeton, NJ  
**Session:** Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

**Presentation #1359:** Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations  
**Lead Author and Presenter:** Michael Amatangelo, Bristol Myers Squibb, Princeton, NJ  
**Session:** Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

**Presentation #1367:** Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis  
**Lead Author and Presenter:** Jesus Berdeja, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN  
**Session:** Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

**Presentation #1378:** Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma  
**Lead Author and Presenter:** Ankit Kansagra, UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX  
**Session:** Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I
<table>
<thead>
<tr>
<th>Presentation #</th>
<th>Title</th>
<th>Lead Author*</th>
<th>Institution and Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1405</td>
<td>Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma</td>
<td>Julie Rytlewski, Bristol Myers Squibb, Princeton, NJ</td>
<td>Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I</td>
<td></td>
</tr>
<tr>
<td>#1418</td>
<td>KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma</td>
<td>Saad Z. Usmani, Levine Cancer Institute, Charlotte, NC</td>
<td>Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I</td>
<td></td>
</tr>
<tr>
<td>#1598</td>
<td>Healthcare Resource Utilization and Cost of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed and Refractory Multiple Myeloma Receiving the BCMA-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Trial</td>
<td>Parameswaran Hari, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI</td>
<td>Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I</td>
<td></td>
</tr>
<tr>
<td>#1603</td>
<td>Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM</td>
<td>Noopur Raje, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA</td>
<td>Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I</td>
<td></td>
</tr>
<tr>
<td>#1653</td>
<td>A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for idecabtagene vicleucel (ide-cel, bb2121), a BCMA Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma</td>
<td>Nina Shah, University of California, San Francisco, CA</td>
<td>Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I</td>
<td></td>
</tr>
</tbody>
</table>

*Presenter differs from lead author
NON-HODGKIN LYMPHOMA

Oral Presentation

Presentation #118: Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001

Lead Author and Presenter: Maria Lia Palomba, Memorial Sloan Kettering Cancer Center, New York, NY

Session: Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma Clinical Trials

Time and Channel: 9:45AM, Channel: 7

Poster Presentations

Presentation #1123: Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance

Lead Author and Presenter: Morton Coleman, Clinical Research Alliance Inc., Weill Cornell Medicine, New York, NY

Session: Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I

Presentation #1196: Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the OUTREACH Study

Lead Author and Presenter: John E. Godwin, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR

Session: Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
# ACUTE MYELOID LEUKEMIA

## Oral Presentations

**Presentation #111:** Escalated Dosing Schedules of CC-486 Are Effective and Well Tolerated for Patients Experiencing First Acute Myeloid Leukemia (AML) Relapse: Results from the Phase III QUAZAR AML-001 Maintenance Trial  
*Lead Author and Presenter:* Hartmut Döhner, Ulm University Hospital, Ulm, Germany  
*Session:* Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel promising therapies for relapsed/refractory AML  
*Time and Channel:* 9:30AM, Channel: 12

**Presentation #214:** Health-Related Quality of Life with CC-486 in Patients with Acute Myeloid Leukemia (AML) in First Remission Following Induction Chemotherapy (IC): Results from the Phase III QUAZAR AML-001 Maintenance Trial  
*Lead Author and Presenter:* Gail J. Roboz, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY  
*Session:* Outcomes Research—Malignant Conditions (Myeloid Disease): Real World Management And Outcome  
*Time and Channel:* 12:15PM, Channel: 4

## Poster Presentations

**Presentation #1008:** Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial  
*Lead Author and Presenter:* Dirk Reinhardt, Department of Pediatric Hematology and Oncology, Essen University Hospital, Essen, Germany  
*Session:* Acute Myeloid Leukemia: Clinical Studies: Poster I

**Presentation #1036:** CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial  
*Lead Author and Presenter:* Andrew Wei, Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia  
*Session:* Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
**MYELODYSPLASTIC SYNDROME**

**Poster Presentations**

**Presentation #1611**: Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Study  
**Lead Author and Presenter**: Esther Natalie Oliva, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy  
**Session**: Health Services Research—Malignant Conditions (Myeloid Disease): Poster I

**Presentation #1617**: Changing Molecular Diagnostic Testing Patterns for Patients (Pts) with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Disease Registry  
**Lead Author and Presenter**: Tracy I. George, ARUP Laboratories, Salt Lake City, UT  
**Session**: Health Services Research—Malignant Conditions (Myeloid Disease): Poster I

**ANEMIA β-THALASSEMIA**

**Poster Presentations**

**Presentation #777**: Rapamycin (Sirolimus) and RAP-536 Increase Red Blood Cell Parameters through Distinct Mechanisms in Wild-Type and Thalassemic Mice  
**Lead Author**: Melih Acar, Formerly Bristol Myers Squibb, Princeton, NJ  
**Session**: Session: Thalassemia and Globin Gene Regulation: Poster I

**Presentation #779**: RAP-536 Induces Reticulocyte Maturation in Wild-Type Mice, Increases Survival of Beta-Thalassemic Reticulocytes, and Increases Red Blood Cells in a Mouse Model of Alpha-Thalassemia  
**Lead Author**: Melih Acar, Formerly Bristol Myers Squibb, Princeton, NJ  
**Session**: Session: Thalassemia and Globin Gene Regulation: Poster I

*Presenter differs from lead author*
# Sunday, December 6

## MULTIPLE MYELOMA

### Oral Presentation

**Presentation #437**: Secondary Quality of Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the BCMA-Directed CAR T cell therapy Idecabtagene Vicleucel (ide-cel, bb2121): Results from the KarMMa Clinical Trial  
**Lead Author and Presenter**: Nina Shah, University of California, San Francisco, CA  
**Session**: Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Myeloma  
**Time and Channel**: 12:15PM, Channel: 11

### Poster Presentations

**Presentation #2295**: Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel CELMoD Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma  
**Lead Author and Presenter**: Lilly Wong, Bristol Myers Squibb, Princeton, NJ  
**Session**: Myeloma: Therapy, excluding Transplantation: Poster II

**Presentation #2314**: Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial  
**Lead Author**: David S. Siegel, Division of Multiple Myeloma, Hackensack University Medical Center, Hackensack, NJ  
**Session**: Myeloma: Therapy, excluding Transplantation: Poster II

**Presentation #2315**: Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized by Early and Temporally Consistent Activation and Expansion of CAR T Cells With a T Effector Phenotype  
**Lead Author and Presenter**: Nathan Martin, Bristol Myers Squibb, Princeton, NJ  
**Session**: Myeloma: Therapy, excluding Transplantation: Poster II

**Presentation #2323**: KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma  
**Lead Author and Presenter**: Michel Delforge, Department of Hematology, University Hospital Leuven, Leuven, Belgium  
**Session**: Myeloma: Therapy, excluding Transplantation: Poster II

*Presenter differs from lead author*
**Presentation #2350:** Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 EVOLVE Study  
**Lead Author**: Julia Piasecki, Bristol Myers Squibb, Seattle, WA  
**Session**: Immunotherapies: Poster II

**Presentation #2358:** Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized by a Predominant Central Memory Phenotype with High In Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence  
**Lead Author and Presenter**: Lucrezia Colonna, Bristol Myers Squibb, Seattle, WA  
**Session**: Cell Collection and Processing: Poster II

---

**HODGKIN LYMPHOMA**

**Oral Presentation**

**Presentation #471:** Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients  
**Lead Author and Presenter**: Christopher A. Yasenchak, Willamette Valley Cancer Institute and Research Center, Eugene, OR  
**Session**: Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma  
**Time and Channel**: 2:15PM Channel: 7

*Presenter differs from lead author*
## NON-HODGKIN LYMPHOMA

### Oral Presentation

**Presentation #340:** Subgroup Analyses of Elderly Patients Aged ≥ 70 years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R² Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

**Lead Author and Presenter:** Frederick Lansigan, Dartmouth–Hitchcock Medical Center, Lebanon, NH

**Session:** Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Clinical studies in Waldenstrom’s Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell Leukemia

**Time and Channel:** 10:30AM, Channel: 8

### Poster Presentations

**Presentation #2045:** Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

**Lead Author*:** Armando Santoro, Humanitas Clinical and Research Center IRCCS, Humanitas University, Milano, Italy

**Session:** Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

**Presentation #2116:** Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

**Lead Author*:** David G. Maloney, Fred Hutchinson Cancer Research Center, Seattle, WA

**Session:** Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II

**Presentation #2514:** Costs of Postinfusion Monitoring by Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND NHL 001 and OUTREACH Trials

**Lead Author and Presenter:** Maria Lia Palomba, Memorial Sloan Kettering Cancer Center, New York, NY

**Session:** Health Services Research—Malignant Conditions (Lymphoid Disease): Poster II

**Presentation #2565:** Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

**Lead Author and Presenter:** Tanya Siddiqi, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

**Session:** Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster II

*Presenter differs from lead author
### ACUTE MYELOID LEUKEMIA

**Poster Presentations**

**Presentation #1912:** Real-World Use of Enasidenib in Relapsed or Refractory Acute Myeloid Leukemia Is Associated with Reduced Risk of Disease Progression and Death  
**Lead Author and Presenter:** Andrew J. Klink, Cardinal Health Specialty Solutions, Dublin, OH  
**Session:** Acute Myeloid Leukemia: Clinical Studies: Poster II

**Presentation #1917:** Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial  
**Lead Author and Presenter:** Farhad Ravandi, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX  
**Session:** Acute Myeloid Leukemia: Clinical Studies: Poster II

**Presentation #2523:** Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Disease Registry  
**Lead Author and Presenter:** Gail J. Roboz, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY  
**Session:** Health Services Research—Malignant Conditions (Myeloid Disease): Poster II

**Presentation #2527:** Indirect Costs of Oral Versus Non-Oral Therapies in Hematologic Malignancies: A Systematic Literature Review  
**Lead Author and Presenter:** Mir Sohail Fazeli, Evidinno Outcomes Research Inc., Vancouver, BC, Canada  
**Session:** Health Services Research—Malignant Conditions (Myeloid Disease): Poster II

### MYELODYSPLASTIC SYNDROME

**Poster Presentations**

**Presentation #2190:** Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the MEDALIST Trial  
**Lead Author and Presenter:** Uwe Platzbecker, Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany  
**Session:** Myelodysplastic Syndromes—Clinical Studies: Poster II
Presentation #2198: The COMMANDS Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions

Lead Author and Presenter: Matteo Della Porta, Cancer Center IRCCS Humanitas Research Hospital, Milan, Italy

Session: Myelodysplastic Syndromes—Clinical Studies: Poster II

Presentation #364: Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the BELIEVE Trial

Lead Author and Presenter: Maria Domenica Cappellini, University of Milan, Milan, Italy

Session: Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease and Beta Thalassemia

Time and Channel: 9:30AM, Channel: 19

Poster Presentations

Presentation #1695: Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the BELIEVE Trial

Lead Author and Presenter: Ali T. Taher, Department of Internal Medicine, American University of Beirut Medical Center Raid El Solh, Beirut, Lebanon

Session: Thalassemia and Globin Gene Regulation: Poster II

Presentation #1697: Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the BELIEVE Trial

Lead Author and Presenter: Olivier Hermine, Imagine Institute, INSERM U1163, University of Paris, Paris, France

Session: Thalassemia and Globin Gene Regulation: Poster II
### MYELOFIBROSIS

**Poster Presentation**

**Presentation #2518**: Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review  
**Lead Author and Presenter**: Francesco Passamonti, Department of Medicine and Surgery, University of Insubria, Varese, Italy  
**Session**: Health Services Research—Malignant Conditions (Myeloid Disease): Poster II

---

### MULTIPLE MYELOMA

**Oral Presentation**

**Presentation #724**: First results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)  
**Lead Author and Presenter**: Neils Van De Donk, Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands  
**Session**: Myeloma/Amyloidosis: Therapy, excluding Transplantation; Novel Approaches for Relapsed/Refractory Myeloma and Amyloidosis  
**Time and Channel**: 1:30PM, Channel: 10

**Poster Presentations**

**Presentation #3234**: Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study  
**Lead Author and Presenter**: Noopur Raje, Massachusetts General Hospital Cancer Center, Boston, MA  
**Session**: Myeloma: Therapy, excluding Transplantation: Poster III

**Presentation #3244**: Clinical Features and Survival Outcomes in Diabetic Patients With Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry  
**Lead Author and Presenter**: Lisa La, Mount Sinai Hospital, New York, NY  
**Session**: Myeloma: Therapy, excluding Transplantation: Poster III
**Presentation #3423**: Association between Spending in Oncology Care Model-Defined Episodes and Overall Survival in Multiple Myeloma Using 2012–2017 Medicare Data  
**Lead Author and Presenter**: Ruben Niesvizky, Multiple Myeloma Center, New York-Presbyterian/Weill Cornell Medical Center, New York, NY  
**Session**: Health Services Research—Malignant Conditions (Lymphoid Disease): Poster III

**Presentation #3465**: Health State Utility Valuation in Patients with Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Treated with the BCMA-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the KarMMa Trial  
**Lead Author and Presenter**: Michel Delforge, Department of Hematology, University Hospital Leuven, Leuven, Belgium  
**Session**: Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster III

### NON-HODGKIN LYMPHOMA

**Presentation #2939**: Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma  
**Lead Author and Presenter**: Jean-Marie Michot, Institut Gustave Roussy, Villejuif, France  
**Session**: Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

### ACUTE MYELOID LEUKEMIA

**Presentation #621**: CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial  
**Lead Author and Presenter**: Esther Natalie Oliva, Division of Hematology, Azienda Ospedaliera (B-M-M), Bologna, Italy  
**Session**: Health Services Research—Malignant Conditions (Myeloid Disease): Treatment and Publication Patterns in Myeloid Malignancies  
**Time and Channel**: 9:15AM, Channel: 14
**Presentation #692**: CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

**Lead Author and Presenter**: Gail J. Roboz, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY

**Session**: Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Dissecting AML heterogeneity to refine treatment approaches

**Time and Channel**: 2:30PM, Channel: 12

**Poster Presentations**

**Presentation #2819**: Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)

**Lead Author and Presenter**: Clara Chen, Bristol Myers Squibb, Princeton, NJ

**Session**: Acute Myeloid Leukemia: Clinical Studies: Poster III

**Presentation #2887**: CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

**Lead Author**: Diana R. Dunshee, Formerly Bristol Myers Squibb, Princeton, NJ

**Session**: Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III

**Presentation #3437**: Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML)

**Lead Author**: Ashley Tabah, Bristol Myers Squibb, Princeton, NJ

**Session**: Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

**Presentation #3444**: Economic Burden of Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Study Using the SEER-Medicare Database

**Lead Author**: Ashley Tabah, Bristol Myers Squibb, Princeton, NJ

**Session**: Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

**Presentation #3488**: Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment

**Lead Author and Presenter**: Tommi Tervonen, Evidera, London, United Kingdom

**Session**: Outcomes Research—Malignant Conditions (Myeloid Disease): Poster III

*Presenter differs from lead author*
**CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA**

### Oral Presentations

**Presentation #544:** TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)

**Lead Author and Presenter:** William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX

**Session:** CLL: Therapy, excluding Transplantation

**Time and Channel:** 7:30AM, Channel: 9

**Presentation #546:** Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of TRANSCEND CLL 004, Including High-Risk and Ibrutinib-Treated Patients

**Lead Author and Presenter:** Tanya Siddiqi, City of Hope National Medical Center, Duarte, CA

**Session:** CLL: Therapy, excluding Transplantation

**Time and Channel:** 8:00AM, Channel: 9

---

**CHRONIC MYELOID LEUKEMIA**

### Poster Presentation

**Presentation #3074:** Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION

**Lead Author and Presenter:** Massimo Breccia, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy

**Session:** Chronic Myeloid Leukemia: Therapy: Poster III
### MYELODYSPLASTIC SYNDROME

**Poster Presentations**

**Presentation #3111:** Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the MEDALIST Study  
**Lead Author and Presenter:** Rami S. Komrokji, Moffitt Cancer Center, Tampa, FL  
**Session:** Myelodysplastic Syndromes—Clinical Studies: Poster III

**Presentation #3486:** Real-World Assessment of Nationwide Health Economic Burden and Treatment-Based Survival for Current Myelodysplastic Syndromes Treatment Practice in Japan  
**Lead Author and Presenter:** Saaya Tsutsué, Celgene K.K., a Bristol-Myers Squibb Company, Tokyo, Japan  
**Session:** Outcomes Research—Malignant Conditions (Myeloid Disease): Poster III

**Presentation #3492:** Physicians’ Experience in Blood Supply Shortages and the Top Factors That Impact the Clinical, Economic, and Humanistic Outcomes of Myelodysplastic Syndrome (MDS) Patients in 5 European Countries  
**Lead Author*:** Shaloo Gupta, Kantar, New York, NY  
**Session:** Outcomes Research—Malignant Conditions (Myeloid Disease): Poster III

### MYELOFIBROSIS

**Poster Presentations**

**Presentation #2992:** Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) – Updated Data from the Phase 2 ACE-536-MF-001 Study  
**Lead Author and Presenter:** Aaron T. Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH  
**Session:** Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III

**Presentation #3006:** Long-Term Safety of Fedratinib in Patients With Intermediate- or High-Risk Myelofibrosis (MF)  
**Lead Author and Presenter:** Animesh Pardanani, Mayo Clinic of Rochester, Rochester, MN  
**Session:** Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III

**Presentation #3442:** Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with a Myelofibrosis Treated with First-Line Ruxolitinib  
**Lead Author*:** Jonathan K. Kish, Cardinal Health, Dublin, OH  
**Session:** Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

*Presenter differs from lead author
# ACUTE MYELOID LEUKEMIA

**Publication #4347:** Annual Healthcare Resource Utilization and Costs in U.S. Patients Diagnosed with Relapsed Acute Myeloid Leukemia  
**Lead Author:** Ashley Tabah, Bristol Myers Squibb, Princeton, NJ

**Publication #4351:** A Systematic Literature Review of Disease Burden and Clinical Efficacy for Patients with Relapsed or Refractory Acute Myeloid Leukemia  
**Lead Author:** Antonio Medina de Almeida, Hospital da Luz, Lisbon, Portugal

**Publication #4354:** Physicians' Perceptions and Use of IDH1/2 Mutational Testing and Treatment Selection Among Patients with Relapsed or Refractory Acute Myeloid Leukemia in Routine Clinical Practice  
**Lead Author:** Andrew J. Klink, Cardinal Health Specialty Solutions, Dublin, OH

# CHRONIC MYELOID LEUKEMIA

**Publication #3963:** A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States  
**Lead Author:** Kathryn Kolibaba, McKesson Life Sciences, McKesson, The Woodlands, TX

**Publication #3966:** Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study  
**Lead Author:** Michael J. Mauro, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering, New York, NY

**Publication #3969:** Real-World Effectiveness of First-Line (1L) Dasatinib Versus 1L Imatinib in Newly Diagnosed Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML)  
**Lead Author:** Andrew J. Klink, Cardinal Health Specialty Solutions, Dublin, OH
### MYELODYSPLASTIC SYNDROME

**Publication #4346**: Real-World Experience with Anemia and Iron Overload Therapies in Myelodysplastic Syndromes (MDS): Treatment Sequence, Duration, and Patient Compliance  
**Lead Author**: Krystal Huey, Bristol Myers Squibb, Princeton, NJ

**Publication #4418**: Association between Transfusion Status (TS) and Clinical and Economic Outcomes in Patients with Myelodysplastic Syndromes (MDS) from the Physicians’ Perspective  
**Lead Author**: Austin Kulasekararaj, King’s College Hospital - NHS Foundation Trust, NIHR Wellcome King’s Clinical Research Facility, London and King’s College London, London, United Kingdom